Clinical Trial Update: Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) [Phase 3]

View source ↗

Summary

Phase 3 trial of apaziquone versus placebo in non-muscle invasive bladder cancer was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Apaziquone (apaziquone)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Bladder Cancer | Phase 3 | Status: TERMINATED | Results posted: 2017-12-15